Legend Biotech Corporation (LEGN)

Market Cap	5.76B
Revenue (ttm)	909.05M
Net Income (ttm)	-239.70M
Shares Out	184.69M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	104.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,544,458
Open	32.62
Previous Close	32.03
Day's Range	29.92 - 33.50
52-Week Range	27.34 - 45.30
Beta	0.07
Analysts	Strong Buy
Price Target	70.82 (+127.17%)
Earnings Date	Nov 12, 2025

About LEGN

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgk...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 2,609
• Stock Exchange: NASDAQ
• Ticker Symbol: LEGN
• Website: https://www.legendbiotech.com

Financial Performance

In 2024, Legend Biotech's revenue was $627.24 million, an increase of 119.97% compared to the previous year's $285.14 million. Losses were -$177.03 million, -65.84% less than in 2023.

Analyst Summary

According to 12 analysts, the average rating for LEGN stock is "Strong Buy." The 12-month stock price target is $70.82, which is an increase of 127.17% from the latest price.

Price Target

$70.82

(127.17% upside)

Analyst Consensus: Strong Buy